8-K: enGene Prices $130M Public Offering of Shares & Warrants

enGene Holdings Inc. announced the pricing of a $130 million public offering of common shares and pre-funded warrants, with an option for underwriters to purchase additional shares.

Summary

• enGene Holdings Inc. priced an underwritten public offering of 12,558,823 common shares at $8.50 per share.
• The offering also included 2,735,295 pre-funded warrants to purchase common shares at an offering price of $8.4999 per pre-funded warrant.
• The aggregate gross proceeds to enGene from the offering are approximately $130 million, before deducting underwriting discounts, commissions, and offering expenses.
• All securities sold in the offering were offered by enGene Holdings Inc.
• Underwriters were granted a 30-day option to purchase up to an additional 2,294,117 common shares at the public offering price, less underwriting discounts and commissions.
• The offering closed on November 14, 2025.
• Each pre-funded warrant has an initial exercise price of $0.0001 per share, subject to certain adjustments, and may be exercised at any time until exercised in full.
• Holders of pre-funded warrants are subject to a beneficial ownership limitation, initially set at 4.99%, 9.99%, or 19.99%, which can be changed by the holder with 61 days' notice.

Sentiment

Score: 7

Explanation: The capital raise provides significant funding for a clinical-stage biotechnology company, which is generally positive for its operational runway and development programs. However, it also involves dilution for existing shareholders, which is a common trade-off in such offerings.

Positives

• The offering is expected to generate approximately $130 million in gross proceeds, strengthening the company's financial position.
• The capital raise provides funding for enGene, a clinical-stage biotechnology company, to continue its development programs.

Negatives

• The issuance of new common shares and pre-funded warrants will result in dilution for existing shareholders.

Risks

• Uncertainties related to market conditions and general economic conditions could impact the company.
• The satisfaction of customary closing conditions related to the offering could pose a risk.
• Other risks and uncertainties are detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission (SEC) on EDGAR, including those described in the Risk Factors section of the company's Annual Report on Form 10-K for the fiscal year ended October 31, 2024.

Future Outlook

enGene's forward-looking statements include expectations regarding the offering's timing, structure, and completion, the underwriters' option, and the potential value and clinical benefit of its product candidates. The company anticipates that subsequent events and developments may cause its assessments to change and disclaims any obligation to update these statements unless required by law.

Management Comments

• enGene Holdings Inc. issued a press release entitled 'enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants' on November 12, 2025.

Industry Context

enGene is a clinical-stage biotechnology company focused on genetic medicine delivery to mucosal tissues and other organs. Its lead program, detalimogene voraplasmid (EG-70), targets non-muscle invasive bladder cancer (NMIBC) and is being evaluated in the LEGEND Phase 2 trial. This capital raise provides crucial funding for continued research and development in the competitive genetic medicine and oncology sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience dilution due to the issuance of new shares and warrants, but benefit from the strengthened financial position of the company.
• Company: Gains significant capital to fund ongoing clinical trials and operations, reducing immediate liquidity concerns.
• Underwriters: Earn commissions and have an option to purchase additional shares, indicating their confidence in the offering.

Key Dates

Keywords

Public Offering, Common Shares, Pre-Funded Warrants, Capital Raise, Biotechnology, Genetic Medicine, NMIBC, SEC Filing, Underwriting Agreement, Dilution